[go: up one dir, main page]

PE20141001A1 - Metoclopramida de liberacion prolongada de 24 horas - Google Patents

Metoclopramida de liberacion prolongada de 24 horas

Info

Publication number
PE20141001A1
PE20141001A1 PE2014000265A PE2014000265A PE20141001A1 PE 20141001 A1 PE20141001 A1 PE 20141001A1 PE 2014000265 A PE2014000265 A PE 2014000265A PE 2014000265 A PE2014000265 A PE 2014000265A PE 20141001 A1 PE20141001 A1 PE 20141001A1
Authority
PE
Peru
Prior art keywords
prolonged release
methchlopramide
pharmaceutical composition
cross links
sodium
Prior art date
Application number
PE2014000265A
Other languages
English (en)
Inventor
Gonzalez Teresita Del Nino Jesus Costales
Vilboeuf John Claude Savoir
Maria Teresa De Jesus Tronocoso
Vargas Miriam Villa
Original Assignee
Posi Visionary Solutions Llp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41114143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20141001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Posi Visionary Solutions Llp filed Critical Posi Visionary Solutions Llp
Publication of PE20141001A1 publication Critical patent/PE20141001A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA DE LIBERACION PROLONGADA QUE COMPRENDE: A) DE 21 A 35 MG DE CLORHIDRATO DE METOCLOPRAMIDA; Y B) DE 179 A 165 MG DE i) UN POLIMERO HIDROFILICO TAL COMO METILCELULOSA, HIDROXIETILCELULOSA, HIDROXIPROPILCELULOSA O HIDROXIPROPILMETILCELULOSA; ii) UN POLIMERO HIDROFOBICO TAL COMO ETILCELULOSA, GLICERIL MONOESTEARATO O ACIDOS GRASOS; Y iii) UN COMPONENTE HIDROFILICO TAL COMO CARBOXIMETILCELULOSA DE SODIO CON ENLACES ENTRECRUZADOS, POLIVINILPIRROLIDONA CON ENLACES ENTRECRUZADOS, ALMIDON GLICOLATO DE SODIO, ALMIDON PREGELATINIZADO O CELULOSA MODIFICADA. DICHA COMPOSICION FARMACEUTICA ES UTIL EN EL TRATAMIENTO DE TRASTORNOS GASTROINTESTINALES
PE2014000265A 2008-03-28 2009-03-27 Metoclopramida de liberacion prolongada de 24 horas PE20141001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2008004268A MX2008004268A (es) 2008-03-28 2008-03-28 Metoclopramida de liberacion prolongada de 24 horas.

Publications (1)

Publication Number Publication Date
PE20141001A1 true PE20141001A1 (es) 2014-08-25

Family

ID=41114143

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2009000458A PE20091737A1 (es) 2008-03-28 2009-03-27 Metoclopramida de liberacion prolongada 12 horas
PE2014000265A PE20141001A1 (es) 2008-03-28 2009-03-27 Metoclopramida de liberacion prolongada de 24 horas
PE2009000459A PE20091824A1 (es) 2008-03-28 2009-03-27 Metoclopramida de liberacion prolongada de 24 horas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2009000458A PE20091737A1 (es) 2008-03-28 2009-03-27 Metoclopramida de liberacion prolongada 12 horas

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2009000459A PE20091824A1 (es) 2008-03-28 2009-03-27 Metoclopramida de liberacion prolongada de 24 horas

Country Status (9)

Country Link
US (1) US20110033536A1 (es)
AR (1) AR071571A1 (es)
BR (1) BRPI0906346A2 (es)
CA (1) CA2757023C (es)
CL (1) CL2009000775A1 (es)
CO (1) CO6311074A2 (es)
MX (1) MX2008004268A (es)
PE (3) PE20091737A1 (es)
WO (1) WO2009120054A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008004267A (es) * 2008-03-28 2009-09-28 Posi Visionary Solutions Llp Metoclopramida de liberacion prolongada de 12 horas.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492661A1 (fr) * 1980-10-28 1982-04-30 Laruelle Claude Nouvelle forme galenique d'administration du metoclopramide, son procede de preparation et medicament comprenant cette nouvelle forme
FR2576213B1 (fr) * 1985-01-21 1989-02-24 Cortial Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee
JPS6261916A (ja) * 1985-09-12 1987-03-18 Fujisawa Pharmaceut Co Ltd 持続性製剤
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US6372254B1 (en) * 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6770262B2 (en) * 2000-03-30 2004-08-03 Questcor Pharmaceuticals, Inc. Nasal administration of agents for the treatment of gastroparesis
KR20040106422A (ko) * 2002-05-01 2004-12-17 노파르티스 아게 간암 및 다른 암 질병 치료용 에포틸론 유도체
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
GB0317904D0 (en) * 2003-07-31 2003-09-03 Jagotec Ag Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
PE20091824A1 (es) 2009-11-25
BRPI0906346A2 (pt) 2016-07-26
WO2009120054A1 (es) 2009-10-01
CA2757023A1 (en) 2009-10-01
CO6311074A2 (es) 2011-08-22
PE20091737A1 (es) 2009-11-25
CA2757023C (en) 2017-09-05
CL2009000775A1 (es) 2009-09-25
US20110033536A1 (en) 2011-02-10
MX2008004268A (es) 2009-09-28
AR071571A1 (es) 2010-06-30

Similar Documents

Publication Publication Date Title
AR082861A1 (es) Forma de dosificacion resistente a alteracion que comprende un polimero anionico
GT200900095A (es) Dihidropirazolonas sustituidas para el tratamiento de enfermedades cardiovasculares y hermatologicas.
ECSP088239A (es) Composición de liberación de fármaco sostenida
EA201071144A1 (ru) Гетероциклические производные
MX2010007295A (es) Composiciones acuosas estables de ciclosporina.
UA105229C2 (uk) Фармацевтичний склад
CO6362012A2 (es) Clohidarto de nalmefeno dihidratado
GT201100336A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas
BR112012013487A2 (pt) Composições de amantadina e métodos de uso
DOP2010000232A (es) Derivados de indazol
PE20081106A1 (es) Comprimidos pediatricos de capecitabina
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
PE20060768A1 (es) Composicion farmaceutica que comprende hidroclorotiazida y telmisartano
PL2244703T3 (pl) Lekarstwo, jego wytwarzanie i zastosowanie w leczeniu bolesnych neuropatii
CY1109865T1 (el) Συνθεσεις βαλσαρτανης
EA201071309A1 (ru) Твердая фармацевтическая композиция
PE20120421A1 (es) Composicion farmaceutica que comprende aleglitazar
UY30021A1 (es) Formulación de suspensión de fexofenadina
BR112013018688A2 (pt) processo para a produção de composição polimérica de proantocianidina
PE20130374A1 (es) Composicion farmaceutica que comprende ibuprofeno
PE20141001A1 (es) Metoclopramida de liberacion prolongada de 24 horas
GT200600277A (es) Derivados de prostaglandina
DOP2006000280A (es) Nuevos derivados de furopirimidina acíclicos sustituidos y su uso
ATE525349T1 (de) Pharmazeutische prostaglandinzusammensetzungen
TN2015000176A1 (fr) Pastille medicamenteuse a base d'ibuprofene sodique dihydrate

Legal Events

Date Code Title Description
FC Refusal
AE Restoration of lapsed or forfeited application
FC Refusal